CEO
Biotech Leaders Urge FDA to ‘Modernise’ Regulation to Compete with China
FDA; biotech; regulation; modernization; China; cell and gene therapy; CEO roundtable; competitiveness; innovation
Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved
Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot
Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock
Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock
Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed
Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio
Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets
Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business
UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO
UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop
Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout
Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company
Brian Armstrongs NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
NewLimit, Brian Armstrong, Coinbase CEO, anti-aging drugs, epigenetic reprogramming, Series B funding, Kleiner Perkins, genetic cell programming, healthy lifespan extension
Alcon Secures Control of Aurion Biotech in Strategic Takeover
Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute